OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Medicine is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Sarcopenia and adverse health‐related outcomes: An umbrella review of meta‐analyses of observational studies	129
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker	88
Development and validation of an immune‐related prognostic signature in lung adenocarcinoma	74
Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer	73
Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma	73
Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy	73
Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index	70
Changing trends in the disease burden of esophageal cancer in China from 1990 to 2017 and its predicted level in 25 years	70
Enhancement of tumor lethality of ROS in photodynamic therapy	70
Depression and prostate cancer risk: A Mendelian randomization study	69
Global trends in the incidence and mortality of esophageal cancer from 1990 to 2017	66
Role of the oral microbiota in cancer evolution and progression	63
Perspectives, fears and expectations of patients with gynaecological cancers during the COVID‐19 pandemic: A Pan‐European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe	63
Liver cirrhosis contributes to the disorder of gut microbiota in patients with hepatocellular carcinoma	59
Patient and clinician experience of a serious illness conversation guide in oncology: A descriptive analysis	58
Disparities in telemedicine during COVID‐19	57
Global, regional and national incidence, mortality and disability‐adjusted life‐years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019	56
Artificial intelligence in oncology: Path to implementation	55
Chinese and global burdens of gastric cancer from 1990 to 2019	53
Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis	52
Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation	51
Chemokines and chemokine receptors: A new strategy for breast cancer therapy	51
Exosome‐mediated delivery of miR‐204‐5p inhibits tumor growth and chemoresistance	51
The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population‐based retrospective matched cohort analysis	50
Protein disulphide isomerase inhibition as a potential cancer therapeutic strategy	48

Comprehensive review of implications of COVID‐19 on clinical outcomes of cancer patients and management of solid tumors during the pandemic	48
Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review	47
Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer	47
Prehabilitation exercise therapy for cancer: A systematic review and meta‐analysis	47
The immune phenotype of tongue squamous cell carcinoma predicts early relapse and poor prognosis	46
Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study	46
Safety and efficacy of photobiomodulation therapy in oncology: A systematic review	46
AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer	46
Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial	45
COVID‐19 and Oncology: Service transformation during pandemic	45
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer	44
Relationship of established risk factors with breast cancer subtypes	44
Magnetically driven microfluidics for isolation of circulating tumor cells	44
Exosomes released from M2 macrophages transfer miR‐221‐3p contributed to EOC progression through targeting CDKN1B	43
Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China	42
The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: A systematic review and meta‐analysis	42
Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR‐520a‐3p/LIMK1 axis	41